Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科伦博泰生物医药股份有限公司

06990.HK

Biopharmaceutical company developing, manufacturing and commercializing novel drugs in oncology and immunology, with a focus on ADC therapeutics. Its core products include a phase 3 TROP2 ADC and an NDA-stage HER2 ADC for advanced solid tumors, plus 12 clinical-stage assets.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Reliance on the controlling shareholder
• Losses and path to profitability
• Net current liabilities or net liabilities
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech